Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,028	$ 19,031
Prepaid expenses and other current assets	549	111
Total current assets	13,577	19,142
Property, equipment and leasehold improvements, net	183	127
Restricted cash - non-current	150	150
Operating lease right-of-use assets	1,039	1,229
Prepaid clinical trial expenses	1,122	1,122
Total assets	16,071	21,770
Current liabilities:
Accounts payable	1,124	605
Operating lease liabilities	378	361
Accrued expenses	905	1,646
Total current liabilities	2,407	2,612
Other liabilities	95	94
Operating lease liabilities - non-current	755	949
Total liabilities	3,257	3,655
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock, $0.00001 par value, authorized 2,000,000 at June 30, 2022 and December 31, 2021. 1,391,160 and 1,370,595 shares issued and outstanding including 200 and 254 shares of unvested restricted stock awards, at June 30, 2022 and December 31, 2021, respectively.	3	3
Additional paid-in capital	256,314	256,241
Accumulated deficit	(243,503)	(238,129)
Total stockholders' equity	12,814	18,115
Total liabilities and stockholders' equity	$ 16,071	$ 21,770